TRAF3IP2 gene variation (rs13190932) in people with psoriasis and psoriatic arthritis
Official title: Genetic Variation in TRAF3IP2 (rs13190932) and Its Association With Psoriasis, Psoriatic Arthritis, and Treatment Outcome With Methotrexate
Run by South Valley University · NCT07086924 · Data updated 2026-11-12
This trial will test whether the TRAF3IP2 (rs13190932) gene variant changes how adults with psoriasis or psoriatic arthritis respond to methotrexate treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | South Valley University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Qina) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | June 1, 2026 |
| Study ends | June 10, 2026 |
| Registry record updated | July 25, 2025 |
| Trial ID | NCT07086924 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 with dermatologist- or rheumatologist-confirmed psoriasis vulgaris or psoriatic arthritis who are about to start methotrexate and can attend follow-up visits are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, already on systemic immunosuppressive therapy, have significant liver or kidney disease, other autoimmune disorders, or cannot start methotrexate are unlikely to benefit from joining this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with confirmed psoriasis or psoriatic arthritis who are starting methotrexate are enrolled and genotyped for the TRAF3IP2 rs13190932 variant. Clinical severity (for example PASI) and safety labs are collected over scheduled follow-up visits to track response and adverse effects while on methotrexate. Patients with other autoimmune diseases, significant liver or kidney impairment, pregnancy/lactation, or on other systemic immunosuppressants are excluded. The approach compares treatment outcomes by genotype to see if the variant predicts methotrexate benefit or toxicity.
Why it matters
Potential benefit: If successful, the results could help predict who is more likely to benefit from methotrexate and guide more personalized treatment decisions.
How similar studies have gone: Prior genetic studies have linked TRAF3IP2 and other loci to psoriasis risk and some work has explored genetics and methotrexate response, but using rs13190932 specifically to guide methotrexate treatment is relatively novel and not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 -70years . * the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist. * Willingness to participate: Signed informed consent. * Initiating methotrexate (MTX) therapy: For prospective cohort. * Availability for follow-up: Patients must be willing and able to attend scheduled visit. Exclusion Criteria: * Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Pregnancy and lactation. * Patients currently undergoing immunosuppressive or systemic therapies. * Patients with known genetic disorders affect immune system function. * Patients with liver or kidney impairment. * Patients with allergy or contraindication to methotrexate. * Patients with active or uncontrolled infections, including chronic infections like tuberculosis. * Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).
Where it's running
-
Qena Hospital
Qina, Egypt Recruiting
Study contacts
- Study coordinator: Fawzia Mohamed Abd Elzaher, MSC
- Email: drfawzia11111995@gmail.com
- Phone: +201001238064
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oral methotrexate versus tofacitinib for chronic plaque psoriasis
This trial will test whether oral methotrexate or tofacitinib works better for adults with moderate-to-severe chronic plaque psoriasis.
-
Investigating a genetic polymorphism in Egyptian patients with psoriatic arthritis
This study is testing if a specific gene variation affects how Egyptian patients with psoriatic arthritis respond to treatment with methotrexate compared to a placebo.
-
Observational study on psoriasis and its risk for arthritis
This study is trying to find out which adults with psoriasis are more likely to develop psoriatic arthritis so that steps can be taken to prevent it.
-
Examining cytokine levels in psoriasis and psoriatic arthritis patients
This study is trying to see how certain proteins in the blood and skin of people with psoriasis and psoriatic arthritis can help us understand these conditions better.
-
Educational tool for melanoma patients with autoimmune diseases
This study is testing a new educational tool to help melanoma patients with autoimmune diseases understand their treatment options better and see how easy it is for them to use.
-
Understanding chronic inflammatory systemic diseases and their treatments
This study looks at patients with chronic inflammatory diseases to see how these conditions are related and how they can be treated better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.